Weekly Top News – Breast Cancer – August 26, 2019

August 26, 2019

Keytruda (pembrolizumab) / Merck (MSD)
Keytruda clinical trial estimate: Data from P3 KEYNOTE-756 trial (NCT03725059) for ER+/HER2- breast cancer in 2031 (Credit Suisse) – Aug 24, 2019 – A subscription to Thomson ONE is required to gain full access to report 67838763; Page no: 18; REPORT TITLE: “Adjuvant Immuno-oncology 2.0: Revisiting potential winners in new $30bn+ market”; AUTHOR: Pharma Team, European, et al; DATE: 08/19/2019


Verzenio (abemaciclib) / Eli Lilly; Imfinzi (durvalumab) / AstraZeneca, Celgene
More cancer meds added to Dutch basic health insurance package (NL Times) – Aug 20, 2019 – “From September 1st the medicines durvalumab and abemaciclib will be covered by the basic health insurance package, Minister Bruno Bruins of Medical Care announced. Durvalumab is used to treat a specific form of lung cancer, abemaciclib is an approved treatment for certain forms of breast cancer.”


Perjeta (pertuzumab) / Roche
Roche’s Perjeta nails new indication approval in China (GBI Health) – Aug 21, 2019 – “Switzerland-based giant Roche announced a new indication approval from China’s National Medical Products Administration (NMPA) in relation to Perjeta (pertuzumab). The drug will be used in combination with sister product Herceptin (trastuzumab) and chemotherapy as an adjuvant therapy for the treatment of patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer (>2 cm in diameter or positive for lymph nodes).”


Trazimera (trastuzumab biosimilar) / Pfizer
Pfizer launches Herceptin biosimilar in Japan (Pharma Japan) – Aug 23, 2019 – “Pfizer Japan said…that its biosimilar version of the major cancer drug Herceptin (trastuzumab) is now available with the exact same indications and dosing schedules as Chugai Pharmaceutical’s originator product.”


Versavo (bevacizumab biosimilar) / Dr. Reddy’s
Dr. Reddy’s Laboratories announces the launch of Versavo (bevacizumab biosimilar) in India(Businesswire) – Aug 19, 2019 – “Dr. Reddy’s Laboratories Ltd…announced…that it has launched Versavo® (bevacizumab), a biosimilar of Roche’s Avastin® in India, indicated for the treatment of several types of cancers (metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer).”


Herzuma (trastuzumab biosimilar) / Nippon Kayaku, Pfizer, Mundipharma, Celltrion, Teva
Japan gives further nod to Celltrion’s breast cancer biosimilar (Korea Biomedical Review) – Aug 22, 2019 – “Celltrion Healthcare said that Japan’s Ministry of Health, Labour and Welfare has approved a three-week cycle method for Herzuma (Ingredient: Trastuzumab), an anticancer antibody biosimilar, in treating breast cancer.”

No Comments

Post a Comment